NASDAQ · STRR
Star Equity Holdings, Inc.
$9.81-$0.07 (-0.71%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
Loading market information…
NYSE · LCI · USD
Stock price, earnings
Quote as of Apr 19, 2023, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lannett Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lannett Company, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:12 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 25, 2021 |
| -$0.76-137.5% vs estimate |
| $106.01M+7.51% vs estimate |
| Q3 2021 | May 5, 2021 | $0.08+140.0% vs estimate | $112.37M-3.22% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$9.81-$0.07 (-0.71%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$3.49+$0.05 (+1.45%)
Neoleukin Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.44% below the high.
$0.14$0.00 (0.0%)
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
$0.43$0.00 (0.0%)
ModivCare Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.68% below the high.
$0.11$0.00 (0.0%)
Tricida, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.22% below the high.
$0.94-$0.01 (-0.53%)
Fresh Tracks Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.44% below the high.
